The Prognostic Value of Neutrophil-to-lymphocyte Ratio and Monocyte-to-lymphocyte Ratio in Metastatic Gastric Cancer Treated with Systemic Chemotherapy
The Prognostic Value of Neutrophil-to-lymphocyte Ratio and Monocyte-to-lymphocyte Ratio in Metastatic Gastric Cancer Treated with Systemic Chemotherapy
复制标题
中性粒细胞与淋巴细胞比值和单核细胞与淋巴细胞比值在转移性胃癌全身化疗中的预后价值
DOI：
10.7150/jca.39575
复制
发表时间：
2020-01-01
影响因子：
3.9
通讯作者：
Zhang, Tao
中科院分区：
文献类型：
--
作者：
Zhou, Danyang;Wu, Ying;Zhang, Tao
背景资料：淋巴细胞/淋巴细胞比值（NLR）和单核细胞/淋巴细胞比值（MLR）在全身化疗治疗的转移性胃癌（mGC）中的预后价值在很大程度上是未知的，尤其是二线化疗。我们回顾性研究了基线NLR和MLR在全身化疗mGC进展中的预后价值。方法：确定2010年1月至2018年12月经病理诊断的mGC患者。在治疗前收集基线NLR和MLR。一线治疗期间或之后的疾病进展时间（PFS 1）和二线化疗期间或之后的疾病进展时间（PFS 2）是主要终点。结果：537例一线化疗患者纳入回顾性研究。NLR和MLR的临界值分别为2.610和0.285。治疗前NLR和MLR是PFS 1的独立预后因素（HR =1.597，95%CI 1.261-2.022，P
Background: The prognostic value of neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) in metastatic gastric cancer (mGC) treated with systemic chemotherapy is largely unknown, especially second-line chemotherapy. We retrospectively investigated the prognostic value of baseline NLR and MLR in the progression of mGC with systemic chemotherapy.Methods: Patients with mGC diagnosed by pathology from January 2010 to December 2018 were identified. Baseline NLR and MLR were collected before treatment. The time to progression during or after first-line therapy from diagnosis (PFS1), and during or after second-line chemotherapy (PFS2) were primary endpoint. Overall survival (OS) was calculated from diagnosis to the date of death or final follow-up.Results: 537 patients with first-line chemotherapy were included in the retrospective study. The cutoff values of NLR and MLR were 2.610 and 0.285, respectively. Pretreatment NLR and MLR were significantly independent prognostic factors for PFS1 (hazard ratio [HR]=1.597, 95% CI 1.261-2.022, P